In light of the previous findings that CX3CR1+CD8+ T cells are essential for viral control and infiltrating to tumour site to reduce tumour growth44,45, our findings raise possible T cell therapies for NPC by infusing the CX3CR1+CD8+ T cells from peripheral blood after ex vivo expansion or engaging chimeric TCR of T cells with CX3CR1 chemotactic potential towards tumour site. The gene discussed is CX3CR1; the disease is neoplasm.